We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.65B
1-Year Est. Return
203.21%
This Fund
S&P 500
This Quarter
Est. Return
-4.94%
1 Year Est. Return
+203.21%
3 Year Est. Return
+364.25%
5 Year Est. Return
+595.91%
10 Year Est. Return
+10,683%
AUM
$662M
AUM Growth
-$58.7M
(-8.2%)
Cap. Flow
-$11.3M
Cap. Flow
% of AUM
-1.71%
Top 10 Holdings %
Top 10 Hldgs %
49.89%
Holding
81
New
8
Increased
13
Reduced
33
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$25M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$21.4M |
| 3 |
AMRN
Amarin Corp
AMRN
|
+$16M |
| 4 |
TRHC
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
|
+$11.2M |
| 5 |
Halozyme
HALO
|
+$10.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
+$56.2M |
| 2 |
Nektar Therapeutics
NKTR
|
+$25.4M |
| 3 |
AERI
Aerie Pharmaceuticals
AERI
|
+$14.1M |
| 4 |
Viatris
VTRS
|
+$10.9M |
| 5 |
Xencor
XNCR
|
+$6.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.02% |
| 2 | Communication Services | 8.27% |
| 3 | Miscellaneous | 5.44% |
| 4 | Industrials | 1.62% |
| 5 | Energy | 0.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OXFD
1
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $61.9M | 9.35% |
3,719,291
+578,944
| +18% | +$8.01M |
|
|
MODN
2
DELISTED
MODEL N, INC.
MODN
| $54.7M | 8.27% |
1,970,044
-208,476
| -10% | -$5.18M |
|
3
Omnicell
OMCL
$1.49B
| $32.9M | 4.98% |
455,737
+124,275
| +37% | +$9.12M |
|
|
MYOK
4
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $27.8M | 4.21% |
533,944
-4,055
| -0.8% | -$216K |
|
5
AtriCure
ATRC
$2.86B
| $27.6M | 4.17% |
1,105,709
-6,031
| -0.5% | -$172K |
|
|
6
Halozyme
HALO
$12.1B
| $26.1M | 3.95% |
1,682,745
+614,932
| +58% | +$10.1M |
|
7
NeoGenomics
NEO
$2.43B
| $25.2M | 3.81% |
1,319,746
-5,836
| -0.4% | -$137K |
|
|
8
Insmed
INSM
$26.2B
| $22.8M | 3.45% |
+1,294,743
| New | +$25M |
|
|
SPNE
9
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $22.6M | 3.42% |
1,852,556
+51,559
| +3% | +$622K |
|
|
XENT
10
DELISTED
Intersect ENT, Inc
XENT
| $20.7M | 3.13% |
1,216,122
+547,229
| +82% | +$9.96M |
|
|
PTLA
11
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $20.5M | 3.1% |
+764,096
| New | +$21.4M |
|
12
Heron Therapeutics
HRTX
$59.6M
| $20.2M | 3.05% |
1,091,110
-7,613
| -0.7% | -$140K |
|
13
Ionis Pharmaceuticals
IONS
$7.85B
| $19.4M | 2.94% |
324,649
-2,483
| -0.8% | -$162K |
|
|
IMMU
14
DELISTED
Immunomedics Inc
IMMU
| $16.6M | 2.51% |
1,250,536
+27,053
| +2% | +$398K |
|
15
Codexis
CDXS
$153M
| $16.4M | 2.48% |
1,198,452
-7,071
| -0.6% | -$111K |
|
|
AMRN
16
Amarin Corp
AMRN
$294M
| $13.9M | 2.11% |
+45,942
| New | +$16M |
|
17
SI-BONE Inc
SIBN
$831M
| $11.4M | 1.73% |
645,982
-5,337
| -0.8% | -$102K |
|
|
18
Xencor
XNCR
$1.77B
| $11.3M | 1.71% |
335,444
-163,900
| -33% | -$6.54M |
|
|
ELGX
19
DELISTED
Endologix Inc
ELGX
| $11.3M | 1.71% |
2,844,317
+381,869
| +16% | +$2.22M |
|
20
Agios Pharmaceuticals
AGIO
$1.96B
| $10.8M | 1.63% |
332,442
+84,545
| +34% | +$3.5M |
|
|
TRHC
21
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $10.7M | 1.62% |
+195,347
| New | +$11.2M |
|
22
Veracyte
VCYT
$3.23B
| $9.86M | 1.49% |
410,925
-178,174
| -30% | -$4.74M |
|
|
VAPO
23
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| $9.7M | 1.47% |
127,967
+65,846
| +106% | +$7.65M |
|
|
ARNA
24
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $8.73M | 1.32% |
190,838
+146,134
| +327% | +$8.21M |
|
25
Tandem Diabetes Care
TNDM
$1.13B
| $8.04M | 1.22% |
136,328
-537
| -0.4% | -$34.3K |
|
Similar funds
AAM
NPA
SOS
BCM
BFO
AAG
MCIL
TIM
First Light Asset Management's Q3 2019 Portfolio in Review
As of Q3 2019, First Light Asset Management held 81 positions worth $662M, down 8.2% from $720M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
First Light Asset Management's Q3 2019 filing shows 8 new, 13 increased, 33 reduced and 10 closed positions. Its largest new stake was Insmed: 1,294,743 shares worth $22.8M. The largest sale was Array Biopharma Inc, an estimated $56.2M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 88% a quarter earlier, followed by Communication Services and Miscellaneous.
- First Light Asset Management's largest Q3 2019 buy was Insmed: 1,294,743 shares worth $22.8M.
- First Light Asset Management added most to Halozyme in Q3 2019, an estimated $10.1M increase.
- First Light Asset Management's biggest Q3 2019 reduction was Viatris, cutting an estimated $10.9M.
- First Light Asset Management fully exited Array Biopharma Inc in Q3 2019, selling an estimated $56.2M.
- First Light Asset Management's ten largest holdings make up 50% of its $662M portfolio in Q3 2019.
- First Light Asset Management opened 8 new positions and closed 10 in Q3 2019.
- First Light Asset Management's portfolio value fell 8.2% quarter-over-quarter to $662M.
Based on First Light Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.